Bristol-myers Squibb Compnay

Stephen W Mamber

Mitsuaki Tsunakawa

John E Leet

Lyndon M Foster

Isia Bursuker

Grace A McClure

Li-Ping Chang

Katie A Thompson

Jingfang Qian Cutrone

Kimberly D Krampitz

Lisa C Rupar

Robert Hugill

Todd Peterson

Joseph O'Sullivan

Todd C Peterson

Craig R Fairchild

Jessica A Gorman

Xiaohong Liu

The present invention relates to xanthone compounds isolated from the plantHochr. (Clusiaceae), a Madagascar plant, which are potent cytotoxic agents.

Cytotoxic xanthone compounds

A novel tyrosyl diester antibiotic is obtained from fermentation of a recombinant strain ofdesignatedWD 15684 (ATCC-202143). The new antibiotic, designated tyrissamycin, exhibits antibacterial activity, particularly against gram-positive bacteria.

Tyrissamycin antibiotic

A novel tyrosyl diester antibiotic is obtained from fermentation of a recombinant strain of,designated,WD 15684 (ATCC-202143). The new antibiotic, designated tyrissamycin, exhibits antibacterial activity, particularly against gram-positive bacteria.

The present invention relates to the novel antitumor antibiotic designated BMS-199687 and to its preparation. The compound is obtained by culturing a new strain of Actinomadura ferruginea. BMS-199687 demonstrates antitumor activity in standard antitumor animal model systems.

Antitumor antibiotic BMS-199687

Ascosteroside, obtainable by cultivation of a strain of Ascotricha amphitricha A.T.C.C. No. 74237, analogs thereof and salts and prodrugs of these compounds. The compounds have antifungal activity for use in a method for treating and preventing a fungal infection. Further, the compounds are useful in a method for inhibiting fungal growth.

Ascosteroside and analogs thereof useful in antifungal compositions for

Growing community of inventors

Annandale, VA, United States of America

Stephen W Mamber